Smith & Nephew plc
HealthcareNYSE:SNN · New York Stock Exchange
-$0.10 today
Vol 0.65M · Avg 1.08M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$12.0B of revenue converted into $1.0B of net income for the selected period. Gross margin is 68.9% and net margin is 8.6%, showing how much revenue survives after costs and taxes. EPS is $2.40, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.2B +6.3% | $5.8B +4.7% | $5.5B +6.4% | $5.2B +0.1% | $5.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.0B +12.1% | $1.8B +2.0% | $1.7B +12.3% | $1.5B -0.2% | $1.5B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $4.2B +3.9% | $4.0B +5.9% | $3.8B +3.9% | $3.7B +0.2% | $3.7B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 68.0% -1.6pp | 69.6% +0.8pp | 68.8% -1.6pp | 70.5% +0.1pp | 70.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $296.7M +2.7% | $289.0M -3.3% | $299.0M -13.3% | $345.0M -3.1% | $356.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $2.9B +9.3% | $2.7B +1.9% | $2.6B +6.9% | $2.4B +1.7% | $2.4B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $3.2B -5.7% | $3.4B -0.1% | $3.4B +5.2% | $3.2B +4.8% | $3.1B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $574.3M -1.0% | $580.0M +10.1% | $527.0M -3.8% | $548.0M -2.7% | $563.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.6B +27.7% | $1.2B +29.4% | $956.0M +9.4% | $874.0M -29.6% | $1.2B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 25.6% +4.3pp | 21.3% +4.1pp | 17.2% +0.5pp | 16.8% -7.1pp | 23.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.0B +53.0% | $657.0M +54.6% | $425.0M +34.9% | $315.0M -46.9% | $593.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 16.3% +5.0pp | 11.3% +3.6pp | 7.7% +1.6pp | 6.0% -5.3pp | 11.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $28.1M +47.7% | $19.0M -44.1% | $34.0M +142.9% | $14.0M +133.3% | $6.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $156.4M -6.9% | $168.0M +20.9% | $139.0M +73.8% | $80.0M +0.0% | $80.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$224.5M -41.2% | -$159.0M -17.8% | -$135.0M -68.8% | -$80.0M -1042.9% | -$7.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $780.8M +56.8% | $498.0M +71.7% | $290.0M +23.4% | $235.0M -59.9% | $586.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 12.6% +4.1pp | 8.6% +3.3pp | 5.2% +0.7pp | 4.5% -6.7pp | 11.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $154.4M +79.5% | $86.0M +218.5% | $27.0M +125.0% | $12.0M -80.6% | $62.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $626.5M +52.1% | $412.0M +56.7% | $263.0M +17.9% | $223.0M -57.4% | $524.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | 10.1% +3.0pp | 7.1% +2.4pp | 4.7% +0.5pp | 4.3% -5.8pp | 10.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +55.3% | $1 -21.7% | $1 +140.0% | $1 -58.3% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +53.2% | $1 -21.7% | $1 +140.0% | $1 -58.3% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $433.4M -1.1% | $438.3M +101.3% | $217.8M -50.2% | $437.6M -0.2% | $438.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $436.5M -0.4% | $438.3M +100.7% | $218.4M -50.1% | $437.6M -0.3% | $438.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Centene Corporation
NYSE:CNC
$32.19B
Royalty Pharma plc
NASDAQ:RPRX
$23.60B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Hologic, Inc.
HOLX
$16.97B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.06B
Tenet Healthcare Corporation
NYSE:THC
$15.04B
Medpace Holdings, Inc.
NASDAQ:MEDP
$13.35B
The Cooper Companies, Inc.
NASDAQ:COO
$13.24B
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
$12.36B
Tempus AI, Inc.
NASDAQ:TEM
$8.35B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SNN generate?
Smith & Nephew plc (SNN) reported $6.18B of revenue in fiscal 2025.
Is SNN profitable?
Smith & Nephew plc (SNN) reported $626.46M of net income, with a net margin of 10.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.